Get started
Author

Hema Artee Luchman

Observed names: A. Luchman, Artee Luchman, H Artee Luchman, H. A. Luchman, H. Artee Luchman, H. Artee Luchmann, H.A. Luchman, H.Artee Luchman, H. Artee Luchman, Hema A. Luchman, Luchman, Hema, Luchman, Hema A, Luchman, Hema Artee
Observed institutions: Memorial University of Newfoundland, Allen Institute for Brain Science, The University of Texas MD Anderson Cancer Center, University of Calgary, University of South Florida, Hospital for Sick Children, Foothills Medical Centre, Moffitt Cancer Center, University of Florida, Canada's Michael Smith Genome Sciences Centre, Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute, Rush University
ORCID: 0000-0002-6663-9929
Observed ORCID: 0000-0002-6663-9929
OpenAlex ID: A5015185322
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity
2021 · Laura M. Richards, Owen K. N. Whitley, et al. · Nature Cancer · 312
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells
2019 · Graham MacLeod, Danielle A. Bozek, et al. · Cell Reports · 239
PRMT5 inhibition disrupts splicing and stemness in glioblastoma
2021 · Patty Sachamitr, Jolene C. Ho, et al. · Nature Communications · 213
PDF
Lactate dehydrogenase A silencing in IDH mutant gliomas
2013 · Charles Chesnelong, Myriam M. Chaumeil, et al. · Neuro-Oncology · 209
An in vivo patient-derived model of endogenous IDH1-mutant glioma
2011 · H. A. Luchman, O. D. Stechishin, et al. · Neuro-Oncology · 198
PDF
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma
2016 · Xueqing Lun, J. Connor Wells, et al. · Clinical Cancer Research · 197
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1
2017 · Tali Mazor, Charles Chesnelong, et al. · Proceedings of the National Academy of Sciences · 138
PDF
Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma
2013 · Sina Haftchenary, H. Artee Luchman, et al. · ACS Medicinal Chemistry Letters · 124
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
2015 · Jose L. Izquierdo-Garcia, Pavithra Viswanath, et al. · Cancer Research · 122
Control of glioblastoma tumorigenesis by feed-forward cytokine signaling
2016 · Arezu Jahani-Asl, Hang Yin, et al. · Nature Neuroscience · 109
PDF
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells
2012 · Owen D. Stechishin, H. Artee Luchman, et al. · Neuro-Oncology · 109
Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival
2021 · Paul Guilhamon, Charles Chesnelong, et al. · eLife · 95
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model
2017 · Katharine Victoria Jensen, Orsolya Cseh, et al. · PLoS ONE · 68
PDF
Hyperpolarized 13C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring
2016 · Myriam M. Chaumeil, Marina Radoul, et al. · NeuroImage Clinical · 67
PDF
Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes
2015 · Carlo Cusulin, Charles Chesnelong, et al. · Stem Cell Reports · 64
PDF
Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments
2019 · Yaoqing Shen, Cameron J. Grisdale, et al. · Proceedings of the National Academy of Sciences · 58
PDF
Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation
2014 · Stephanie A. Nguyen, Owen D.M. Stechishin, et al. · Clinical Cancer Research · 58
Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
2014 · H. Artee Luchman, Owen D.M. Stechishin, et al. · Clinical Cancer Research · 55
2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas
2018 · Pavithra Viswanath, Marina Radoul, et al. · Cancer Research · 54
cDNA Cloning of a Novel, Developmentally Regulated Immediate Early Gene Activated by Fibroblast Growth Factor and Encoding a Nuclear Protein
1997 · Gary D. Paterno, Yu Li, et al. · Journal of Biological Chemistry · 50
Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin
2013 · F. J. Zemp, X. Lun, et al. · Neuro-Oncology · 49
PDF
Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas
2021 · Pavithra Viswanath, Georgios Batsios, et al. · Neuro-Oncology · 45
PDF
Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
2018 · Pavithra Viswanath, Marina Radoul, et al. · Cancer & Metabolism · 44
PDF
Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway
2020 · Ian J. Restall, Orsolya Cseh, et al. · Cancer Research · 42
PDF
Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors
2015 · Brad Davis, Yaoqing Shen, et al. · Neuro-Oncology · 41
Works count: 172
Citation count: 3,327
H-index: 32
I10-index: 45
Year
Topic
Type